Benitec Biopharma Inc Stock

$11.35

8.10% yesterday

Nasdaq, Jun 27, 10:16 pm CET

ISIN

US08205P1003

Symbol

BNTC

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Benitec Biopharma Inc Stock price

$11.35

-124.40 91.64% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

-1.00 8.10%

ISIN

US08205P1003

Symbol

BNTC

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$297.9m

Enterprise Value

$194.4m

Net debt

$-103.6m

Cash

$103.6m

Shares outstanding

25.6m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

2.97

Dividends

DPS

$0.00

Yield 1Y | 5Y

0.00% | 0.00%

Growth 1Y | 5Y

- | -

Payout 1Y | 3Y

0.00% | 0.00%

Increased

0 Years

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-29.8m | $-26.1m

EBIT

$-30.1m

Net Income

$-27.1m | $-33.5m

Free Cash Flow

$-18.7m

Growth (TTM | estimate)

Revenue

-100.00% | -

EBITDA

-40.16% | -17.89%

EBIT

-40.22%

Net Income

-24.99% | -49.58%

Free Cash Flow

8.29%

Margin (TTM | estimate)

Gross

EBITDA

- | -

EBIT

Net

- | -

Free Cash Flow

EPS

$-0.70

FCF per Share

$-0.73

Short interest

3.68%

Employees

16.00

Rev per Employee

$0.00

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Benitec Biopharma Inc Stock Analysis

Unlock Scores for Free

??

13 Analysts have issued a Benitec Biopharma Inc forecast:

12x Buy

92%

More details on Analyst Estimates Including Price Targets

13 Analysts have issued a Benitec Biopharma Inc forecast:

Buy

92%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Benitec Biopharma Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	14 14	128% 128% -
- Research and Development Expense	16 16	3% 3% -
EBITDA	-30 -30	40% 40% -
- Depreciation and Amortization	0.37 0.37	48% 48% -
EBIT (Operating Income) EBIT	-30 -30	40% 40% -
Net Profit	-27 -27	25% 25% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Benitec Biopharma Inc Stock News

Positive

Seeking Alpha

●

2 months ago

Benitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy Developer

We initiate a Buy rating for Benitec Biopharma due to promising early data from BB 301 for OPMD and a cash runway into mid-2027. BB 301 shows potential for meaningful improvements in swallowing function, with significant commercial opportunities and an undervalued stock price reflecting high-dose cohort data. Financially, Benitec has no revenue, rising operating expenses, and a cash balance of ...

Negative

24/7 Wall Street

●

3 months ago

Insiders Are Loving These 5 Tech and Biotech Stocks

After struggling through a rough patch, the biotech industry seems to be staging a comeback.

Neutral

GlobeNewsWire

●

3 months ago

Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering

HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) “Silence and Replace” platform, today announced the pricing of its underwritten offering of 1,443,000 shares of it...

More Benitec Biopharma Inc News

Company Profile

Benitec Biopharma, Inc. is a development-stage biotechnology company, which focuses on the advancement of novel genetic medicines. The firms proprietary platforms includes DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy, and Chronic Hepatitis B. The company was founded on April 13, 2020 and is headquartered in Hayward, CA.

Head office	United States
CEO	Jerel Banks
Employees	16
Founded	2019
Website	benitec.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now